VIVOSIM LABS INC
VIVSNASDAQTrading Snapshot
- Day Range
- $0.35 – $0.36
- 52-Week Range
- $0.31 – $5.30
- Volume
- $3.26B
- Avg Volume
- $4.20B
- Shares Outstanding
- 12.1M
- Next Earnings
- Sep 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $131,000
- Last Q Revenue
- $40,000
- P/E Ratio
- —
- P/S Ratio
- 29.3x
- EPS (TTM)
- $-5.33
- Dividend Yield
- —
Why Investors Own VIVS
- ✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 55% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About VIVOSIM LABS INC
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings of 23 cents per share and sales of $20.898 million. Other stocks gaining pre-market include DarkIris Inc (NASDAQ:DKI), Jin Medical International Ltd (NASDAQ:ZJYL), and Volato Group Inc (NYSE:SOAR).
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of their
VivoSim Labs Receives Nasdaq Noncompliance Notice, Gets Time Through Sept. 3 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/1497253/000121390026081377/ea0299224-8k_vivo.htm
In today's session, these stocks are experiencing unusual volume.
Discover the stocks with unexpected trading volume in today's session on the US markets.
VivoSim Labs Announces First Commercial Sales In China For Its NAMkind Testing Services
, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.